Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefadroxil hemihydrate
Drug ID BADD_D00380
Description Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
Indications and Usage For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes
Marketing Status approved; vet_approved; withdrawn
ATC Code J01DB05
DrugBank ID DB01140
KEGG ID D02353; D00257
MeSH ID D002434
PubChem ID 67173987
TTD Drug ID D0X9ZC
NDC Product Code 16714-390; 43063-553; 57237-096; 57237-098; 63629-7987; 63629-8253; 66267-045; 68180-180; 68788-8479; 65862-359; 16714-389; 72189-445; 80425-0198; 65862-085; 50090-6050; 63629-7988; 68180-182; 68071-5234; 16714-388; 45865-503; 63187-883; 68071-2752; 70518-2538; 50090-0580; 57237-097; 68788-7484; 68788-8261; 0093-3196; 0093-4059; 43063-595; 65862-083; 65862-084; 70518-3580; 72189-103; 50090-6356; 55289-589; 68180-181; 67296-1038; 68071-2938; 53002-2290
UNII J9CMF6461M
Synonyms Cefadroxil | Cephadroxyl | Cefadroxil Anhydrous | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Ultracef | Bidocef | Duricef | BL-S 578 | BL S 578 | BLS 578 | BL-S578 | BL S578 | BLS578 | S-578 | S 578 | S578 | 4-Hydroxycephalexin | 4 Hydroxycephalexin | Cefadroxil Monohydrate
Chemical Information
Molecular Formula C32H36N6O11S2
CAS Registry Number 119922-85-9
SMILES CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O.CC1=C(N2C(C(C2=O)NC(=O)C(C3 =CC=C(C=C3)O)N)SC1)C(=O)O.O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.04.005--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Aplastic anaemia01.03.03.002--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Blood bilirubin increased13.03.04.018--
Blood creatinine increased13.13.01.004--
Blood lactate dehydrogenase increased13.04.02.002--
Blood urea increased13.13.01.006--Not Available
Cholestasis09.01.01.001--Not Available
Diarrhoea07.02.01.001--
Dyspepsia07.01.02.001--
Eosinophilia01.02.04.001--
Erythema multiforme23.03.01.003; 10.01.03.015--
Genital candidiasis21.10.03.001; 11.03.03.002--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001--Not Available
Hypersensitivity10.01.03.003--
Nausea07.01.07.001--
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Neutropenia01.02.03.004--Not Available
Pancytopenia01.03.03.003--Not Available
Prothrombin time prolonged13.01.02.012--Not Available
Pruritus genital23.03.12.008; 21.10.01.002--Not Available
Pseudomembranous colitis11.02.02.002; 07.19.01.003--Not Available
Pyrexia08.05.02.003--
Serum sickness12.02.08.004; 10.01.03.004--
The 1th Page    1 2    Next   Last    Total 2 Pages